| http://www.w3.org/ns/prov#value | - er said the company decided to close the La Jolla facility???s programs in small-molecule drugs for metabolic and inflammatory conditions because they duplicate efforts elsewhere in the company.Instead, he said, Tanabe will seek to build capabilities in La Jolla in the kinds of ???biologic drugs??? that biotechnology companies have developed for cancer and other conditions.He said the plan is to s
|
